Hypogalactia Clinical Trial
Official title:
Effect of Acupuncture on Hypogalactia (Decreased Milk Supply): A Pilot Study
NCT number | NCT03851718 |
Other study ID # | L18-195 |
Secondary ID | |
Status | Withdrawn |
Phase | N/A |
First received | |
Last updated | |
Start date | June 2019 |
Est. completion date | June 2020 |
Verified date | May 2019 |
Source | Texas Tech University Health Sciences Center |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The specific aims are (1) to assess the feasibility of a RCT studying acupuncture's impact on breast milk production, and (2) to compare the difference of milk production between acupuncture and power pumping. The study approach will be a two-site prospective, non-blinded, two-arm randomized clinical trial conducted in Lubbock and Amarillo as a collaborative effort between researchers and clinicians in the departments of Family Medicine, Pediatrics and Ob/Gyn. An estimated 60 eligible mothers will be recruited and enrolled in the study from both sites. The participants will be randomized 1:1 into either the intervention group or the comparison group. The intervention group will receive three standardized acupuncture sessions, based on previous studies done in China and investigators' practice protocol, in 5 days and the comparison group will perform power pumping in 5 days per provided manual and guidance. The primary outcome is changes of breast milk production and it will be measured by weighing the grams/volume of milk expressed with an electric breast pump over time. The secondary outcome is changes of plasma prolactin and it will be measured by immunoassay. Data will be collected at baseline, right after interventions and two week after interventions to compare the difference of the outcomes. The findings of this study will provide insight to establish a RCT protocol to assess acupuncture's impact on hypogalactia. It may also help establish evidence of acupuncture use for hypogalactia.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | June 2020 |
Est. primary completion date | December 2019 |
Accepts healthy volunteers | No |
Gender | Female |
Age group | 18 Years to 45 Years |
Eligibility |
Inclusion Criteria: 1. Primipara or Multipara woman who had normal pregnancy (gestation = 37 weeks gestation) and gave birth vaginally or by Caesarean section to a single child without complications and who are 2 weeks to 6 months postpartum. 2. Estimated milk production of < 450 g/24 hours (or 450ml/24hours)-by self-report 3. A current body mass index (BMI) equal or above 18 kg/m2 and below 35 kg/ m2 4. Non-smoker. Subjects who have stopped smoking for >6 months prior to study start may be included. 5. Must be fluent in English conversation, reading and writing. Exclusion Criteria: 1. Presence or a history of clinically significant diseases of the renal, hepatic, gastrointestinal, cardiovascular, musculoskeletal systems or presence or history of clinically significant psychiatric, immunological, endocrine or metabolic diseases including gestational or pregestational diabetes, and Polycystic Ovarian syndrome. 2. History of breast cancer, breast surgery, or clinically significant abnormalities of the breasts that may affect the milk production and/or flow. 3. Use of typical and atypical antipsychotics, drugs/supplements, and/or other approaches that may increase milk production or prolactin levels in patients. 4. Consumes alcohol during breastfeeding. 5. Current case of infectious mastitis and/or Reynaud's disease of the breast. 6. History within the last two years or current abuse of alcohol or drugs. 7. Current non-smokers with a history of long-term, heavy smoking (>10 pack-years). |
Country | Name | City | State |
---|---|---|---|
United States | Texas Tech University Health Sciences Center | Lubbock | Texas |
Lead Sponsor | Collaborator |
---|---|
Texas Tech University Health Sciences Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | changes of breast milk production volume from based line to within 48 hours after the last intervention session. | Breast Milk Production will be measured by weighing the grams/volume of milk expressed with an electric breast pump (e.g. Spectra Baby USA) at four sequential hourly intervals including zero time. | Measurements will be done during the study at baseline and right after (i.e. within 48 hours) after last acupuncture session or power pumping secession. | |
Primary | changes of breast milk production volume from based line to at 2 weeks after the last intervention session. | Breast Milk Production will be measured by weighing the grams/volume of milk expressed | Measurements will be done during the study at baseline and 2 weeks after last acupuncture session or power pumping secession. | |
Secondary | changes of prolactin level from based line from based line to within 48 hours after the last intervention session. | the participants will have 7 ml of blood drawn by venipuncture utilizing a serum separator tube. A blood collection log and labels will be created. The sample will be taken to the laboratory, allowed to clot and then centrifuged at 2500-3200 rpm for 5-6 minutes to separate the serum from the cells. Samples will be analyzed for prolactin using a Beckman Coulter Access 2 Immunoassay Analyzer and an FDA approved in vitro diagnostic Prolactin assay kit according to clinical standards. | Measurements will be done during the study at baseline and right after (i.e. within 48 hours) after last acupuncture session or power pumping secession. | |
Secondary | changes of prolactin level from based line to 2 weeks after the last intervention session. | the participants will have 7 ml of blood drawn by venipuncture utilizing a serum separator tube. A blood collection log and labels will be created. The sample will be taken to the laboratory, allowed to clot and then centrifuged at 2500-3200 rpm for 5-6 minutes to separate the serum from the cells. Samples will be analyzed for prolactin using a Beckman Coulter Access 2 Immunoassay Analyzer and an FDA approved in vitro diagnostic Prolactin assay kit according to clinical standards. | Measurements will be done during the study at baseline and 2 weeks after last acupuncture session or power pumping secession. |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03577587 -
Efficacy of Herbal Galactagogue Silitidil After Preterm Birth
|
N/A |